Lantern Pharma Completes Targeted Enrollment for Phase 2 HARMONIC Clinical Trial in Japan Ahead of Schedule
TL;DR
Lantern Pharma's early completion of Phase 2 HARMONIC trial enrollment in Japan positions it ahead in targeting never-smoker NSCLC markets with its AI-driven LP-300 therapy.
Lantern Pharma's Phase 2 HARMONIC trial uses the RADR platform to assess LP-300 combined with carboplatin and pemetrexed in never-smoker NSCLC patients post tyrosine kinase inhibitors.
Lantern Pharma's AI-driven cancer therapies aim to improve survival rates and quality of life for never-smoker NSCLC patients globally, starting with Japan and Taiwan.
Lantern Pharma leverages AI to fast-track cancer drug development, showing an 86% clinical benefit rate in early U.S. trials for never-smoker NSCLC.
Found this article helpful?
Share it with your network and spread the knowledge!
Lantern Pharma (NASDAQ: LTRN), a pioneer in AI-driven oncology drug development, has announced the completion of targeted enrollment for its Phase 2 HARMONIC clinical trial in Japan, achieving this milestone ahead of schedule. The trial, which enrolled 10 patients across five sites including the National Cancer Center Japan, focuses on evaluating the efficacy of LP-300 in combination with carboplatin and pemetrexed for never-smoker non-small cell lung cancer (NSCLC) patients who have progressed after tyrosine kinase inhibitors. This development underscores the company's strategic expansion into regions with a higher prevalence of never-smoker NSCLC, such as Japan and Taiwan, where enrollment is ongoing alongside U.S. sites.
The global HARMONIC trial aims to enroll approximately 90 patients, building on promising early U.S. data that showed an 86% clinical benefit rate, including a durable complete response lasting nearly two years. Lantern Pharma's CEO, Panna Sharma, highlighted the significance of this achievement, noting it validates the company's approach to leveraging its proprietary RADR platform for accelerating oncology drug discovery and development. The RADR platform utilizes over 100 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms to address complex challenges in cancer treatment.
For more details on Lantern Pharma's innovative approach to cancer therapy and the HARMONIC trial, visit https://ibn.fm/IcDma. The company's efforts represent a significant advancement in the fight against cancer, offering hope to patients worldwide with its AI-driven pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers.
Curated from InvestorBrandNetwork (IBN)
